27017-64-7

Upstream product

• 141-32-2 acrylic acid n-butyl ester 
• 135795-46-9 2-bromo-6-methoxy-pyridin-3-ylamine 
• 19293-63-1 dicyclohexylmethylamine 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 34392-85-3 3-amino-2-chloro-6-methoxypyridine 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 27017-70-5 1,5-dihydro-1,5-naphthyridine-2,6-dione 

Relevant academic research and scientific papers

A novel bis-lactam acceptor with outstanding molar extinction coefficient and structural planarity for donor-acceptor type conjugated polymer

A novel electron-accepting bis-lactam building block, 3,7-dithiophen-2-yl-1,5-dialkyl-1,5-naphthyridine-2,6-dione (NTDT), and a conjugated polymer P(NTDT-BDT) comprising NTDT as an electron acceptor and benzo[1,2-b:4,5-b′]dithiophene (BDT) as an electron donor are designed and synthesized for producing efficient organic solar cells. The thermal, electronic, photophysical, electrochemical, and structural characteristics of NTDT and P(NTDT-BDT) are studied in detail and compared with those of the widely used bis-lactam acceptor 3,6-dithiophen-2-yl-2,5-dialkylpyrrolo[3,4-c]pyrrole-1,4-dione (DPPT) and its polymer P(DPPT-BDT). Compared to DPPT derivatives, NTDT and P(NTDT-BDT) exhibit remarkably higher absorption coefficients, deeper highest occupied molecular orbital energy levels, and more planar conformations. A bulk heterojunction solar cells based on P(NTDT-BDT) exhibit power conversion efficiency of up to 8.16% with high short circuit current (Jsc) of 18.51 mA cm-2, one of the highest Jsc values yet obtained for BDT-based polymer. Thus, it is successfully demonstrated that the novel bis-lactam unit NTDT is a promising building block for use in organic photovoltaic devices.

ORGANIC SEMICONDUCTOR

The invention relates to novel compounds containing one or more units derived from 1,5-disubstituted-1,5-dihydro-[1,5]naphthyridine-2,6-dione, to methods for their preparation and educts or intermediates used therein, to mixtures and formulations containing them, to the use of the compounds, mixtures and formulations as organic semiconductors in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these compounds, mixtures or formulations.

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against mycobacterium tuberculosis

DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restrict their clinical value. We describe a novel class of N-linked aminopiperidinyl alkyl quinolones and naphthyridones that kills Mtb by inhibiting the DNA gyrase activity. The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as shown by their ability to inhibit the growth of fluoroquinolone-resistant Mtb. Biochemical studies demonstrated this class to exert its action via single-strand cleavage rather than double-strand cleavage, as seen with fluoroquinolones. The compounds are highly bactericidal against extracellular as well as intracellular Mtb. Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability. Compounds from this series are efficacious in various murine models of tuberculosis.

CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I Z-L-R1-Q-D-(V1)m-R2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R1, Q, D, V1, m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.